



MEMBERSHIP

Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending February 29, 2024 [Japanese GAAP]

January 11, 2024

Company name: Hisamitsu Pharmaceutical Co., Inc.
 Stock exchange listing: Tokyo, Nagoya, Fukuoka
 Securities code: 4530
 URL: <https://global.hisamitsu/>
 Representative: NAKATOMI Kazuhide, President & CEO
 Contact: ISOBE Yuichi, Executive Officer, Department General Manager of Corporate Strategy Planning and Business Development
 TEL: +81-3-5293-1704
 Scheduled date of filing quarterly securities report: Jan. 12, 2024
 Scheduled date of dividend payment: —
 Preparation of supplementary materials for quarterly financial results: Yes
 Holding of quarterly financial results meeting: Yes (for institutional investors and analysts, etc.)

(Amounts are rounded down to the nearest millions of yen)

1. Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending February 29, 2024 (March 1, 2023 to November 30, 2023)

(1) Consolidated Operating Results

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended Nov. 30, 2023	102,827	11.9	12,270	44.2	16,661	28.1	12,110	27.2
Nine months ended Nov. 30, 2022	91,881	6.0	8,506	22.0	13,003	50.1	9,522	53.1

(Note) Comprehensive income: Nine months ended Nov. 30, 2023 27,871 millions of yen [(8.6%)]
 Nine months ended Nov. 30, 2022 30,499 millions of yen [226.2%]

	Profit per share	Diluted profit per share
	yen	yen
Nine months ended Nov. 30, 2023	156.64	156.48
Nine months ended Nov. 30, 2022	119.46	119.36

(2) Consolidated Financial Position

	Total assets	Net assets	Shareholders' equity ratio
	Millions of yen	Millions of yen	%
As of Nov. 30, 2023	334,909	271,496	80.3
As of Feb. 28, 2023	313,917	258,408	81.6

(Reference) Shareholders' equity: As of Nov. 30, 2023 268,773 millions of yen
 As of Feb. 28, 2023 256,105 millions of yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Fourth quarter	Total
	yen	yen	yen	yen	yen
Year ended Feb. 28, 2023	—	42.25	—	42.25	84.50
Year ending Feb. 29, 2024	—	42.50	—		
Year ending Feb. 29, 2024 (Forecast)				42.50	85.00

(Note) Revisions to the most recently announced dividends forecast: No

3. Consolidated Earnings Forecast for the Fiscal Year Ending February 29, 2024 (March 1, 2023 to February 29, 2024)

(Percentages represent year-on-year changes)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Profit per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	yen
Full year	141,000	9.9	14,400	24.1	19,900	24.0	14,600	24.3	188.85

(Note) Revisions to the most recently announced consolidated forecast: Yes

*Notes

- (1) Changes in significant subsidiaries during the period : None
(Changes in specified subsidiaries resulting in changes in scope of consolidation)
- (2) Application of special accounting methods for preparation of quarterly consolidated financial statements : Yes
- (3) Changes in accounting policies, changes in accounting estimates, and restatement
- 1) Changes in accounting policies due to revision of accounting standards : None
 - 2) Changes in accounting policies other than 1) above : None
 - 3) Changes in accounting estimates : None
 - 4) Restatement : None
- (4) The number of shares outstanding (common stock)
- 1) Total number of shares outstanding at the end of the period (including treasury stock)
 - As of Nov. 30, 2023 85,164,895 shares
 - As of Feb. 28, 2023 85,164,895 shares
 - 2) Total number of treasury stock at the end of the period
 - As of Nov. 30, 2023 9,055,141 shares
 - As of Feb. 28, 2023 7,420,560 shares
 - 3) Average number of shares outstanding during the period
 - Nine months ended Nov. 30, 2023 77,310,355 shares
 - Nine months ended Nov. 30, 2022 79,715,046 shares

*Quarterly financial results reports are not subjected to quarterly review.

*Explanation for appropriate use of financial forecasts and other special notes

Among this document, the forecasts based on the plan may changes due to uncertain factors. Therefore, the actual operating results may differ from the company's view.

Financial settlement briefings for institutional investors and analysts will be held on January 11, 2024. Presentation materials of financial results will be posted promptly on the company's website after the financial settlement briefings.

Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance sheets

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 28, 2023)	Current Third Quarter (As of Nov. 30, 2023)
Assets		
Current assets		
Cash and deposits	122,154	111,141
Notes and accounts receivable - trade, and contract assets	40,014	42,412
Securities	14,714	12,771
Merchandise and finished goods	10,330	11,834
Work in process	562	1,031
Raw materials and supplies	8,030	8,741
Other	3,629	12,553
Allowance for doubtful accounts	(261)	(303)
Total current assets	199,174	200,181
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	13,980	17,213
Other, net	29,229	33,811
Total property, plant and equipment	43,209	51,025
Intangible assets		
Sales rights	394	358
Goodwill	—	4,649
Other	551	557
Total intangible assets	946	5,566
Investments and other assets		
Investment securities	60,845	67,616
Other	9,948	10,707
Allowance for doubtful accounts	(207)	(188)
Total investments and other assets	70,586	78,136
Total non-current assets	114,742	134,728
Total assets	313,917	334,909

(Millions of yen)

	Prior Fiscal Year End (As of Feb. 28, 2023)	Current Third Quarter (As of Nov. 30, 2023)
Liabilities		
Current liabilities		
Notes and accounts payable - trade	8,351	10,052
Electronically recorded obligations - operating	6,567	6,315
Short-term loans payable	1,071	1,071
Income taxes payable	2,338	2,315
Provision for bonuses	1,340	678
Other	22,908	29,913
Total current liabilities	42,578	50,346
Non-current liabilities		
Long-term loans payable	147	95
Net defined benefit liability	8,408	8,587
Other	4,375	4,383
Total non-current liabilities	12,931	13,066
Total liabilities	55,509	63,412
Net assets		
Shareholders' equity		
Capital stock	8,473	8,473
Capital surplus	2,361	2,361
Retained earnings	235,569	241,100
Treasury shares	(27,196)	(35,341)
Total shareholders' equity	219,208	216,594
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	17,042	21,802
Revaluation reserve for land	3,403	3,402
Foreign currency translation adjustment	15,819	26,505
Remeasurements of defined benefit plans	631	467
Total accumulated other comprehensive income	36,896	52,178
Share acquisition rights	260	313
Non-controlling interests	2,042	2,410
Total net assets	258,408	271,496
Total liabilities and net assets	313,917	334,909

(2) Quarterly Consolidated Statements of Income and Comprehensive Income

Quarterly Consolidated Statements of Income

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2022 – Nov. 30, 2022)	Current Fiscal Year (Mar. 1, 2023 – Nov. 30, 2023)
Net sales	91,881	102,827
Cost of sales	39,100	44,227
Gross profit	52,781	58,600
Selling, general and administrative expenses	44,274	46,330
Operating profit	8,506	12,270
Non-operating income		
Interest income	398	1,806
Dividend income	626	705
Foreign exchange gains	3,210	1,446
Share of profit of entities accounted for using equity method	—	83
Other	452	431
Total non-operating income	4,687	4,472
Non-operating expenses		
Interest expenses	12	12
Share of loss of entities accounted for using equity method	35	—
Loss on cancellation of insurance policies	—	47
Cost for idle operation	95	—
Other	46	21
Total non-operating expenses	189	80
Ordinary profit	13,003	16,661
Extraordinary income		
Gain on disposal of non-current assets	142	1
Total extraordinary income	142	1
Extraordinary losses		
Loss on disposal of non-current assets	116	3
Total extraordinary losses	116	3
Profit before income taxes	13,029	16,659
Income taxes	3,208	4,179
Profit	9,821	12,480
Profit attributable to non-controlling interests	299	370
Profit attributable to owners of parent	9,522	12,110

Quarterly Consolidated Statements of comprehensive income

(Millions of yen)

	Prior Fiscal Year (Mar. 1, 2022 – Nov. 30, 2022)	Current Fiscal Year (Mar. 1, 2023 – Nov. 30, 2023)
Profit	9,821	12,480
Other comprehensive income		
Valuation difference on available-for-sale securities	2,928	4,644
Foreign currency translation adjustment	18,021	10,795
Remeasurements of defined benefit plans, net of tax	(240)	(140)
Share of other comprehensive income of entities accounted for using equity method	(31)	92
Total other comprehensive income	20,678	15,391
Comprehensive income	30,499	27,871
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	30,104	27,392
Comprehensive income attributable to non-controlling interests	395	479



Our commitments originate from each individual's determination to "start something good for ecology (eco)!"

Hisamitsu Pharmaceutical has designed the "HELLO! eco!" mark as a symbol of its environmental activities,

and products that have met the ecology standards that our company has established will display the "HELLO! eco!" mark sequentially.

Hisamitsu.